undamentalytics Newsletter
Sign in

Anbio Biotechnology revenue

Anbio Biotechnology's revenue was $8.6m in fiscal 2025, up 5.6% on the year before. Since fiscal 2022 ($23.5m) it has grown at a compound -28.4% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue24789
Growth on the year before—−71.5%+21.9%+5.6%
Gross profit13368
Gross margin53.4%50.1%71.9%87.2%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Health Care Equipment: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Anbio Biotechnology $8.6m 5.6% —
Nuwellis, Inc. $9.0m 8.4% 2.8%
Milestone Scientific Inc. $9.4m 3.7% -1.9%
Neuroone Medical Technologies Corp $9.5m 42.8% 94.9%
Beyond Air, Inc. $7.7m 60.7% 122.7%
Work Medical Technology Group LTD $9.8m -14.4% —

Compare with peers

Head to head: NNNN vs NUWEMLSS vs NNNNNMTC vs NNNNNNNN vs XAIR

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Anbio Biotechnology's SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Anbio Biotechnology.